Aurora A/B kinase (with secondary FGFR1/2/3, VEGFR1, JAK1/2, CSF1R inhibition)

Class

spectrum-selective, small-molecule multi-kinase inhibitor; predominant activity is Aurora A/B inhibition (IC50 1.2/3.3 nM) with additional potent inhibition of FGFR1/2/3, VEGFR1, JAK1/2, and CSF1R

Pathway

Aurora A/B inhibition blocks mitotic kinase activity causing G2/M cell-cycle arrest; concurrent FGFR/JNK-JUN pathway inhibition and MEK/ERK-dependent apoptotic pathway activation contribute to anti-tumor activity, shown to be active against triple-negative breast cancer models

Aurora A and Aurora B are serine/threonine kinases — enzymes that add phosphate groups to other proteins — that orchestrate the physical process of cell division (mitosis). Aurora A helps organize the mitotic spindle and centrosome maturation, while Aurora B ensures chromosomes attach correctly and separate evenly before cells split. Rapidly dividing cancer cells depend heavily on these kinases; blocking them halts cells at the G2/M checkpoint, a control point before division, and can trigger cell death.

This particular agent inhibits Aurora A/B as its primary action but also inhibits several other kinases — FGFR1/2/3, VEGFR1, JAK1/2, and CSF1R — at meaningful potency. This spectrum-selective profile aims to simultaneously interrupt tumor cell proliferation (Aurora), growth-factor signaling that tumors use to resist therapy (FGFR), blood vessel formation that feeds tumors (VEGFR1), inflammatory signaling within the tumor microenvironment (JAK), and macrophage-supported tumor survival (CSF1R). The rationale is that hitting several complementary pathways at once may overcome the redundancy that allows tumors to escape single-pathway inhibition. This mechanism is broadly relevant to aggressive, difficult-to-treat solid tumors, including triple-negative breast cancer, where cell-cycle and angiogenic pathways jointly support tumor growth.